Labcorp has expanded its MRD testing portfolio with new personalized panels for breast and lung cancer and nationwide whole-genome MRD testing for stage III colon cancer, enabling earlier detection of recurrence via ctDNA analysis.
AI, new diagnostics, and shifting care delivery models are among the clinical laboratory predictions for 2026.
New recommendations address evolving drug landscape and advancing testing technologies since original 2003 guidance.
The autonomous robotic phlebotomy system uses imaging, robotics, and AI to identify veins and complete routine diagnostic blood draws.
The collaboration will combine New Day's liquid biopsy technology with Daisy Genomics' physics-based sequencing platform to advance early CRC screening.
